Elevated Serum Cholesterol in Asymptomatic Adults

  • Steven H. Woolf
Part of the Frontiers of Primary Care book series (PRIMARY)


Recent clinical trials such as the Lipid Research Clinics (LRC) Coronary Primary Prevention Trial1,2 and, more recently, the Helsinki Heart Study3 have demonstrated that lowering serum cholesterol can reduce the incidence of coronary heart disease (CHD) in middle-aged men with hyperlipidemia. Beginning in 1984, these findings have stimulated the encouragement of the public to consume less dietary fat and the promotion of detection and treatment of persons with hyperlipidemia. Physicians, in particular, received specific guidelines from the National Institutes of Health Consensus Conference on Lowering Blood Cholesterol4 and the National Cholesterol Education Program5 to measure serum cholesterol and prescribe appropriate dietary and/or pharmacologic interventions to reduce serum lipids to a “desirable” level.


Serum Cholesterol Coronary Heart Disease Risk Serum Cholesterol Level Coronary Heart Disease Event Coronary Heart Disease Mortality 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Lipid Research Clinics Program. Lipid Research Clinics Coronary Primary Prevention Trial results:I.Reduction in incidence of coronary heart disease. JAMA 1984;251:351–64.CrossRefGoogle Scholar
  2. 2.
    Lipid Research Clinics Program. Lipid Research Clinics Coronary Primary Prevention Trial results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984;251:365–74.CrossRefGoogle Scholar
  3. 3.
    Frick MH, Elo O, Haapa K, et al. Helsinki Heart study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237–45.PubMedCrossRefGoogle Scholar
  4. 4.
    National Institutes of Health. Lowering blood cholesterol to prevent heart disease. JAMA 1985;253:2080–86.CrossRefGoogle Scholar
  5. 5.
    National Institutes of Health. Cholesterol Counts: Steps for Lowering Your Patient’s Blood Cholesterol. NIH Publ. No. 85-2699. Bethesda, Md: 1985.Google Scholar
  6. 6.
    National Cholesterol Education Program Expert Panel. Report on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med 1988;148:36–69.CrossRefGoogle Scholar
  7. 7.
    National Center for Health Statistics. Advancereport of final mortality statistics, 1986. Monthly Vital Statistics Report, Vol. 37, No. 6 (Suppl) DHHS Publ No. (PHS) 88–1120. Hyattsville, Md: Public Health Service, 1988.Google Scholar
  8. 8.
    National Center for Health Statistics. Health, United States, 1988. DHHS Publ No. (PHS) 89-1232. Washington: Public Health Service, 1986, 41.Google Scholar
  9. 9.
    Sempos C, Fulwood R, Haines C, et al. The prevalence of high blood cholesterol levels among adults in the United States. JAMA 1989;262:45–52.PubMedCrossRefGoogle Scholar
  10. 10.
    Palumbo PJ. Cholesterol lowering for all: a closer look. JAMA 1989;262:91–92.PubMedCrossRefGoogle Scholar
  11. 11.
    Wilson PWF, Christiansen JC, Anderson KM, et al. Impact of national guidelines for cholesterol risk factor screening: the Framingham Offspring study. JAMA 1989;262:41–44.PubMedCrossRefGoogle Scholar
  12. 12.
    Brett AS. Treating hypercholesterolemia: how should practicing physicians interpret the published data for patients? N Engl J Med 1989;321:676–79.PubMedCrossRefGoogle Scholar
  13. 13.
    Moore TJ. The cholesterol myth. The Atlantic Monthly 1989(Sept): 37–70.Google Scholar
  14. 14.
    Office of Technology Assessment. Costs and effectiveness of cholesterol screening in the elderly. Washington: 1989.Google Scholar
  15. 15.
    Garber AM, Sox HC Jr, Littenberg B. Screening asymptomatic adults for cardiac risk factors: the serum cholesterol level. Ann Intern Med 1989;110:622–39.PubMedGoogle Scholar
  16. 16.
    Ontario Ministry of Health. Task Force on the Use and Provision of Medical Services. Detection and management of asymptomatic hypercholesterolemia. Ottawa: 1989.Google Scholar
  17. 17.
    Smith WCS, Davis AM, Kenicer MB, et al. Blood cholesterol: is population screening warranted in the UK? Lancet 1989;1:372–73.PubMedCrossRefGoogle Scholar
  18. 18.
    Stare FJ. The AMA’s campaign against cholesterol (letter). JAMA 1989;261:3240–41.PubMedCrossRefGoogle Scholar
  19. 19.
    Stamler J. Lifestyles, major risk factors, proof and public policy. Circulation 1978;58:3–19.PubMedGoogle Scholar
  20. 20.
    Stallones RA. Ischemic heart disease and lipids in blood and diet. Annu Rev Nutr 1983;3:155–85.PubMedCrossRefGoogle Scholar
  21. 21.
    Grundy SM. Cholesterol and coronary heart disease: a new era. JAMA 1986;256:2849–58.PubMedCrossRefGoogle Scholar
  22. 22.
    Dayton S, Pearce ML, Hashimoto S, et al. A controlled clinical trial of a diet high in unsaturated fat in preventing complications of atherosclerosis. Circulation 1969;40:(suppl 2):1–63.Google Scholar
  23. 23.
    Borhani NO. Primary prevention of coronary heart disease: a critique. Am J Cardiol 1977;40:251–59.PubMedCrossRefGoogle Scholar
  24. 24.
    Hjermann I, Velve Byre K, Holme I, et al. Effect of diet and smoking intervention on the incidence of coronary heart disease: report from the Oslo Study Group of a randomized trial in healthy men. Lancet 1981;2:1303–10.PubMedCrossRefGoogle Scholar
  25. 25.
    Ahrens EH. The diet-heart question in 1985: has it really been settled? Lancet 1985;1:1085–89.PubMedCrossRefGoogle Scholar
  26. 26.
    Multiple Risk Factor Intervention Trial Research Group. Multiple Risk Factor Intervention Trial: risk factor changes and mortality results. JAMA 1982;248:1465–77.CrossRefGoogle Scholar
  27. 27.
    World Health Organization, European Collaborative Group. European collaborative trial of multifactorial prevention of coronary heart disease: final report on the 6-year results. Lancet 1986;1:869–72.Google Scholar
  28. 28.
    Rinzler S. Primary prevention of coronary heart disease by diet. Bull NY Acad Med 1968;44:936–49.Google Scholar
  29. 29.
    Turpeinen O, Karvonen MJ, Pekkarinen M, et al. Dietary prevention of coronary heart disease: the Finnish Mental Hospital study. Int J Epidemiol 1979;8:99–118.PubMedCrossRefGoogle Scholar
  30. 30.
    Miettinen M, Turpeinen O, Karvonen MJ, et al. Effect of cholesterol-lowering diet on mortality from coronary heart disease and other causes: a twelve-year clinical trial in men and women. Lancet 1972;2:835–38.PubMedCrossRefGoogle Scholar
  31. 31.
    Stamler J. Acute myocardial infarction: progress in primary prevention. Br Heart J 1971;33:145–64.PubMedCrossRefGoogle Scholar
  32. 32.
    Frantz ID, Dawson EA, Kuba K. The Minnesota Coronary Survey: effect of diet on cardiovascular events and deaths (abstr). Circulation 1975;52(suppl II):4.Google Scholar
  33. 33.
    Committee of Principal Investigators. A cooperative trial in the primary prevention of ischaemic heart disease using clofibrate. Br Heart J 1978;40:1069–1118.CrossRefGoogle Scholar
  34. 34.
    Committee of Principal Investigators. WHO cooperative trial on primary prevention of ischaemic heart disease using clofibrate to lower serum cholesterol: mortality follow-up. Lancet 1980;2:379–85.Google Scholar
  35. 35.
    Committee of Principal Investigators. WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Lancet 1984;2:600–604.Google Scholar
  36. 36.
    Lipid Research Clinics Program. The Coronary Primary Prevention Trial: design and implementation. J Chronic Dis 1979;32:609–631.CrossRefGoogle Scholar
  37. 37.
    Lipid Research Clinics Program. Pre-entry characteristics of participants in the Lipid Research Clinics Coronary Primary Prevention Trial. J Chron Dis 1983;36:467–79.CrossRefGoogle Scholar
  38. 38.
    Lipid Research Clinics Program. Participant recruitment to the Coronary Primary Prevention Trial. J Chronic Dis 1983;36:451–65.CrossRefGoogle Scholar
  39. 39.
    Kolata G. Heart panel’s conclusions questioned. Science 1985;227:40–41.PubMedCrossRefGoogle Scholar
  40. 40.
    Kronmal RA. Commentary on the published results of the Lipid Research Clinics Coronary Primary Prevention Trial. JAMA 1985;253:2091–93.PubMedCrossRefGoogle Scholar
  41. 41.
    Lipid Research Clinics Program Investigators. Reply to commentary by Richard Kronmal. JAMA 1985;254:263–64.CrossRefGoogle Scholar
  42. 42.
    Rahimtoola SH. Some unexpected lessons from large multicenter randomized clinical trials. Circulation 1985;72:449–55.PubMedCrossRefGoogle Scholar
  43. 43.
    Borhani NO. Prevention of coronary heart disease in practice: implications of the results of recent clinical trials. JAMA 1985;254:257–262.PubMedCrossRefGoogle Scholar
  44. 44.
    Taylor WC, Pass TM, Shepard D, et al. Cholesterol reduction and life expectancy: a model incorporating multiple risk factors. Ann Intern Med 1987;106:605–14.PubMedGoogle Scholar
  45. 45.
    Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? JAMA 1986;256:2823–28.PubMedCrossRefGoogle Scholar
  46. 46.
    Martin MJ, Hulley SB, Browner WS, et al. Serum cholesterol, blood pressure, and mortality: implications from a cohort of 361,662 men. Lancet 1986;2:933–36.PubMedCrossRefGoogle Scholar
  47. 47.
    Anderson KM, Castelli WP, Levy D. Cholesterol and mortality: 30 years of follow-up from the Framingham study. JAMA 1987;257:2176–80.PubMedCrossRefGoogle Scholar
  48. 48.
    Neaton JD, Kuller LH, Wentworth D, et al. Total and cardiovascular mortality in relation to cigarette smoking, serum cholesterol concentration, and diastolic blood pressure among black and white males followed up for five years. Am Heart J 1984;108:759–70.PubMedCrossRefGoogle Scholar
  49. 49.
    Harlan WR, Stross JK. An educational view of a national initiative to lower plasma lipid levels. JAMA 1985; 253:2087–90.PubMedCrossRefGoogle Scholar
  50. 50.
    Wynder EL, Field F, Haley NJ. Population screening for cholesterol determination: a pilot study. JAMA 1986;256:2839–42.PubMedCrossRefGoogle Scholar
  51. 51.
    Fihn SD. A prudent approach to control of cholesterol levels. JAMA 1987;258::2416–18.Google Scholar
  52. 52.
    Blackburn H. Public policy and dietary recommendations to reduce population level of blood cholesterol. Am J Prev Med 1985;1:3–11.PubMedGoogle Scholar
  53. 53.
    American Heart Association. 1989 Heart Facts. Dallas: 1988.Google Scholar
  54. 54.
    Lefebvre RC, Hursey KG, Carleton RA. Labeling of participants in high blood pressure screening pro-grams: implications for blood cholesterol screenings. Arch Intern Med 1988;148:1993–97.PubMedCrossRefGoogle Scholar
  55. 55.
    Blank DW, Hoeg JM, Kroll MH, et al. The method of determination must be considered in interpreting blood cholesterol levels. JAMA 1986;256:2767–70.CrossRefGoogle Scholar
  56. 56.
    Jacobs DR, Barrett-Connor E. Retest reliability of plasma cholesterol and triglyceride: the Lipid Research Clinics Prevalence Study. Am J Epidemiol 1982;116:878–85.PubMedGoogle Scholar
  57. 57.
    Wyngaarden JB. Variability in individual cholesterol level clouds risk assessment. JAMA 1988;260:759.Google Scholar
  58. 58.
    Serum Cholesterol Determinations. Med Lett 1987;29:41–42.Google Scholar
  59. 59.
    Burke JJ II, Fischer PM. A clinician’s guide to the office measurement of cholesterol. JAMA 1988;259:3444–48.PubMedCrossRefGoogle Scholar
  60. 60.
    Koch TR, Mehta U, Lee H, et al. Bias and precision of cholesterol analysis by physician’s office analyzers. Clin Chem 1987;33:2262–67.PubMedGoogle Scholar
  61. 61.
    Kroll MH, Lindsey H, Greene J, et al. Bias between enzymatic methods and the reference method for cholesterol. Clin Chem 1988;34:131–35.PubMedGoogle Scholar
  62. 62.
    Rastam L, Admire JB, Frantz ID, et al. Measurement of blood cholesterol with the Reflotron analyzer evaluated. Clin Chem 1988;34:26.Google Scholar
  63. 63.
    Hicks JM, Iosefsohn M. Another physician’s office analyzer: the Abbott “Vision” evaluated. Clin Chem 1987;33:817– 19.PubMedGoogle Scholar
  64. 64.
    Nanji AA, Sincennes F, Poon R, et al. Evaluation of the Boehringer Mannheim “Reflotron” analyzer. Clin Chem 1987;33:1254–55.PubMedGoogle Scholar
  65. 65.
    von Schenck H, Treichl L, Tilling B, et al. Laboratory and field evaluation of three desktop instruments for assay of cholesterol and triglyceride. Clin Chem 1987;33:1230–32.Google Scholar
  66. 66.
    Lasater TM, Lefebvre RC, Assaf AR, et al. Rapid measurement of blood cholesterol: evaluation of a new instrument. Am J Prev Med 1987;3:311–16.PubMedGoogle Scholar
  67. 67.
    Belsey R, Vandenbark M, Goitein RK, et al. Evaluation of a laboratory system intended for use in physicians’ offices: II. Reliability of results produced by health care workers without formal or professional training. JAMA 1987;258:357–61.PubMedCrossRefGoogle Scholar
  68. 68.
    Laboratory Standardization Panel of the National Cholesterol Education Program. Current status of blood cholesterol measurement in clinical laboratories in the United States. Clin Chem 1988;34:193–201.Google Scholar
  69. 69.
    Cotton P. CAP moves to improve lipid tests. Medical World News 1988 (June):55.Google Scholar
  70. 70.
    Oliver MF. Risks of correcting the risks of coronary disease and stroke with drugs. N Engl J Med 1982;306:297–98.PubMedCrossRefGoogle Scholar
  71. 71.
    Knodel LC, Talbert RL. Adverse effects of hypolipidaemic drugs. Med Toxicol 1987;2:10–32.PubMedGoogle Scholar
  72. 72.
    Oster G, Epstein AM. Cost-effectiveness of anti hyperlipemic therapy in the prevention of coronary heart disease: the case of cholestyramine. JAMA 1987;258:2381–87.PubMedCrossRefGoogle Scholar
  73. 73.
    Lovastatin for hypercholesterolemia. Med Lett 1987;29:99–101.Google Scholar
  74. 74.
    Blum CB, Levy RI. Current therapy for hyper-cholesterolemia. JAMA 1989;261:3582–87.PubMedCrossRefGoogle Scholar
  75. 75.
    Peterson B, Trell E, Sternby NH. Low cholesterol level as risk factor for noncoronary death in middle-aged men. JAMA 1981;245:2056–57.PubMedCrossRefGoogle Scholar
  76. 76.
    Miller SR, Tartter PI, Papatestas AE, et al. Serum cholesterol and human colon cancer. JNCI 1981;67:297–300.PubMedGoogle Scholar
  77. 77.
    Rose G, Shipley MJ. Plasma lipids and mortality: a source of error. Lancet 1980;2:523–526.CrossRefGoogle Scholar
  78. 78.
    Neugut Al, Johnsen CM, Fink DJ. Serum cholesterol levels in adenomatous polyps and cancer of the colon: a case-control study. JAMA 1986;255:365–67.PubMedCrossRefGoogle Scholar
  79. 79.
    International Collaborative Group. Circulating cholesterol level and risk of death from cancer in men aged 40 to 69 years. JAMA 1982;248:2853–59.CrossRefGoogle Scholar
  80. 80.
    Williams RR, Sorlie PD, Feinleib M, et al. Cancer incidence by levels of cholesterol. JAMA 1981;245:247–252.PubMedCrossRefGoogle Scholar
  81. 81.
    Sherwin RW, Wentworth DN, Cutler JA, et al. Serum cholesterol levels and cancer mortality in 361,662 men screened for the Multiple Risk Factor Intervention Trial. JAMA 1987;257:943–48.PubMedCrossRefGoogle Scholar
  82. 82.
    Castelli WP, Garrison RJ, Wilson PW, et al. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham study. JAMA 1986;256:2835–38.PubMedCrossRefGoogle Scholar
  83. 83.
    Wilson PW, Abbott RD, Castelli WP. High density lipoprotein cholesterol and mortality: the Framingham Heart study. Arteriosclerosis 1988;8:737–41.PubMedCrossRefGoogle Scholar
  84. 84.
    Herman M. Health Care Financing Administration. Personal communication, February 1989.Google Scholar

Copyright information

© Springer-Verlag New York Inc. 1990

Authors and Affiliations

  • Steven H. Woolf

There are no affiliations available

Personalised recommendations